-
Posted by
Two Blokes May 23, 2025 -
Filed in
Stock
-
5 views
The recent stock drop in Bicara Therapeutics Inc. is an overreaction, as the full phase 1/1b data—including key OS results—has yet to be released. BCAX interim data for FICERA plus KEYTRUDA in HPV-negative HNSCC patients showed a 64% ORR, exceeding historical benchmarks and highlighting a significant unmet need. Upcoming ASCO 2025 data and FDA alignment on Accelerated Approval using ORR as an endpoint create a compelling near-term catalyst for investors.
